Outro raised $7 million to help people quit antidepressants. The trials haven't caught up.

A startup bets on quitting, not starting

Outro Health raised $7 million in combined pre-seed and seed funding, the company announced on October 8, 2026, with Listen Ventures, Cake Ventures, Jason Calacanis's LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group and Pave Health Ventures all putting in money. The pitch from cofounder and CEO Brandon Goode is blunt: "We've built the on-ramp for medications. Now it is time to build the off-ramp."

That off-ramp is Taper Management, a program that pairs patients with clinicians to slowly reduce antidepressant doses, track symptoms and offer support along the way. It currently runs in 14 states, with plans to expand into other drug classes once the antidepressant program scales.

The timing fits a real gap. About one in six Americans takes an antidepressant, by Outro's own figures, and the average course now runs past five years, well beyond the eight to twelve week trials the FDA originally approved these drugs on. Investor Ellen Wilcox of Listen Ventures puts the current number of users at roughly 50 million.

The science behind the slow taper

Outro's method is not invented marketing. Cofounder Dr. Mark Horowitz coauthored the 2019 paper that proposed hyperbolic tapering: cutting doses in progressively smaller steps rather than equal ones, because the relationship between SSRI dose and serotonin transporter binding is itself hyperbolic. Small cuts near the end of a taper have an outsized effect, which is why standard step downs can trigger severe withdrawal in long term users.

Britain's NICE health guidance body updated its depression guidelines back in October 2019 to acknowledge that withdrawal symptoms can last months, not the week or two the older guidance assumed. A detailed clinical review lays out the numbers: a 2019 systematic review found 56% of people who try to stop an antidepressant report withdrawal symptoms, and 46% of those call them severe. Horowitz's own research, cited in Outro's announcement, found four in five long term users could not stop because of withdrawal.

What $7 million actually buys

Neither Outro nor its investors disclosed a valuation, a lead investor, or how the $7 million splits between the pre-seed and seed tranches, typical for a round this size but worth noting. The money is earmarked for three things: growing the clinician network, building AI tools into the tapering workflow, and expanding beyond antidepressants into other drug classes, plausibly benzodiazepines given Horowitz's research background.

What is missing from the announcement is any outcome data of Outro's own. No patient count, no completion rate, no measure of how many users actually finished tapering versus gave up partway through. For a company whose entire premise is doing deprescribing better than a rushed primary care visit, that gap matters.

The distance between the pitch and the proof

Here is the honest state of the evidence. Hyperbolic tapering has a sound pharmacological rationale, a published framework and growing clinical acceptance. What it does not yet have is a completed randomized controlled trial measuring it against standard tapering. One write-up of the funding round notes that a 2026 study protocol lays out exactly that comparison, but it is a protocol, not results. Horowitz is also a collaborator on trials in Australia testing supported hyperbolic tapering, which likewise haven't reported final outcomes.

That doesn't make the approach wrong. It makes it unproven in the specific, controlled way medicine usually demands before calling something standard of care, which is the language Wilcox used to describe where she thinks Outro is headed. Right now it's a reasonable, biologically grounded practice backed mostly by observational data and researcher experience, not by trial results Outro can point to for its own 14 state program.

Who this actually helps

If you've tried to come off an antidepressant and been told to just halve the dose for two weeks, you've likely met the gap Outro is trying to fill. A slower, monitored taper matches what the evidence and bodies like NICE now recommend over abrupt cuts. But Outro is a venture backed startup running in 14 states, not a nationwide benefit, and it hasn't said what it costs out of pocket or whether insurance touches it. Readers who followed our look at which new mental health treatments actually hold up will recognize the pattern: real biology behind the pitch, thinner trial evidence behind the specific product built on it.

Our take

Outro is tackling a real problem with a defensible method, and Horowitz's research gives it more scientific weight than most funded wellness startups can claim. But $7 million buys a clinician network and some AI tooling, not a randomized trial, and the numbers describing the scale of the withdrawal problem are far more solid than any numbers describing how well Outro itself performs. If you're trying to come off an antidepressant, talk to the clinician who prescribed it first, taper slowly either way, and treat "we built the off-ramp" as a pitch, not a verdict.

Health Trend Wire holds no position in Outro and was not paid for this article. This is general information, not medical or financial advice.